氟桂利嗪和倍他司汀治疗良性位置性眩晕及其伴随症状的临床疗效比较

The comparison of therapeutic effects on benign paroxysmal positional vertigo and associated symptoms between flunarizine and betahistine

目的观察氟桂利嗪与倍他司汀治疗良性位置性眩晕(BPPV)及其伴随症状的临床疗效。方法将182例BPPV的患者随机分为氟桂利嗪治疗组和倍他司汀治疗组。氟桂利嗪治疗组给予氟桂利嗪进行常规治疗,倍他司汀治疗组施以倍他司汀治疗。两组均治疗8周为1个疗程并进行随访。比较两种药物治疗眩晕及伴随症状的疗效。结果治疗8周后,氟桂利嗪治疗眩晕的疗效高于倍他司汀(χ2=4.4138,P<0.05),在治疗头痛、自主神经伴随症状方面,氟桂利嗪的疗效也均高于倍他司汀(均P<0.01),而在治疗耳鸣方面,两组疗效比较无统计学差异(χ2=3.3442,P>0.05)。结论氟桂利嗪治疗BPPV及其伴随症状具有较好的疗效。

Objective To evaluate the therapeutic effects of flunarizine and betahistine on benign paroxysmal positional vertigo （BPPV） and associated symptoms. Methods In a multicenter double-blind study, one hundred and eighty-two adult patients with BPPV were treated with flunarizine （5/10 mg on bedtime） or betahistine dichlorhydrate （12 mg 3 times daily） for 8 weeks, The therapeutic effects of these two drugs on vertigo and associated symptoms （tinnitus, headache and neurovegetative disorders） were compared. Results Flunarizine was significantly more effective on vertigo attacks （X2 = 4. 4138, P〈0.05） and associated symptoms （mainly neurovegetative disorders and headaches） （P〈0.01, respectively）. Flunarizine and betahistine showed similar efficacy on tinnitus （X2 = 3. 3442, P 〉0.05）. Conclusions This study indicates that the calcium antagonist flunarizine is superior to betahistine on the treatment of vestibular vertigo.